CT imaging of and therapy for inflammatory bowel disease <i>via</i> low molecular weight dextran coated ceria nanoparticles.

ABSTRACT: Inflammatory bowel disease (IBD) affects approximately 3.1 million individuals in the U.S., causing deleterious symptoms such as bloody diarrhea and leading to an increased risk of colorectal cancer. Effective imaging is crucial for diagnosing and managing IBD, as it allows for accurate assessment of disease severity, guides treatment decisions, and monitors therapeutic responses. Computed tomography (CT) with contrast agents is the gold standard for imaging the gastrointestinal tract (GIT). However, current agents are less effective in obese patients and lack specificity for inflamed regions associated with IBD. Moreover, IBD treatments often have limited efficacy and do not address the role of oxidative stress in IBD progression. This study explores dextran-coated cerium oxide nanopartic

SUBMITTER: Rosario-Berrios DN 

PROVIDER: S-EPMC11967712 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature